CYTK - Cytokinetics, Incorporated -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg ยท closes rebased to 100 at each year's first session
Ticker Details
Cytokinetics, Incorporated
Cytokinetics Inc is a biopharmaceutical company. It is engaged in the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
IPO Date: May 1, 2004
Sector: Healthcare
Industry: Biotech
Market Cap: $8.5B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.48 | 3.05%
Avg Daily Range (30 D): $1.36 | 1.93%
Avg Daily Range (90 D): $1.42 | 1.87%
Institutional Daily Volume
Avg Daily Volume: .63M
Avg Daily Volume (30 D): 1.65M
Avg Daily Volume (90 D): 1.63M
Trade Size
Avg Trade Size (Sh.): 98
Avg Trade Size (Sh.) (30 D): 58
Avg Trade Size (Sh.) (90 D): 59
Institutional Trades
Total Institutional Trades: 10,274
Avg Institutional Trade: $3.4M
Avg Institutional Trade (30 D): $6.06M
Avg Institutional Trade (90 D): $5.4M
Avg Institutional Trade Volume: .08M
Avg Institutional Trades (Per Day): 4
Market Closing Trades
Avg Closing Trade: $8.62M
Avg Closing Trade (30 D): $27.69M
Avg Closing Trade (90 D): $26.74M
Avg Closing Volume: 190.61K
 
News
Oct 2, 2026 @ 11:30 AM
Cytokinetics Announces Four Upcoming Presentations...
Source: Na
Sep 18, 2026 @ 1:15 PM
AbbVie vs. Bristol Myers Squibb: Which Healthcare ...
Source: Sara Appino
Sep 4, 2026 @ 7:36 PM
Will Camzyos' Long-Term Benefits Strengthen BMY's ...
Source: Na
Sep 2, 2026 @ 8:00 PM
Cytokinetics to Participate in September Investor ...
Source: Na
Sep 2, 2026 @ 6:30 PM
Can CYTK's Aficamten Strengthen Its HCM Growth Pro...
Source: Na
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-7.22 $-1.5 $-1.67
Diluted EPS $-7.22 $-1.5 $-1.67
Revenue $67.67M $28.62M $19.36M
Gross Profit
Net Income / Loss $-894M $-198.76M $-206.03M
Operating Income / Loss $-707.91M $-179.17M $-183.62M
Cost of Revenue
Net Cash Flow $181.83M $125.42M $7.32M
PE Ratio    
Splits
Jun 25, 2013 1:6